Amarin EXPECTS FDA Approval and 3 Stock Analyses Not to be Missed

IAC/InterActiveCorp. (NASDAQ:IACI), according to Benchmark Co. has momentum in search and  Match is sustainable. The firm maintains a Buy rating on the stock.

Don’t Miss: Cisco Gets Thumbs-Up For This HUGE BUY.

Triumph Group, Inc. (NYSE:TGI) has been added to the U.S. 1 List at BofA/Merrill.

Cardinal Health, Inc. (NYSE:CAH): UBS thinks Cardinal Health will re-up its contract with Express Scripts/Medco and will make an announcement in coming weeks.

Amarin Corporation plc‘s (NASDAQ:AMRN) AMR101 is expected by Roth Capital to get full FDA approval for the MARINE population, and to be bought out or to enter into a major international partnership. Shares of Amarin are Buy rated with a $21 price target.

Don’t Miss: AT&T Earnings: Margins EXPAND, Rings Up More Profit.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.